Your browser is no longer supported. Please, upgrade your browser.
Graybug Vision, Inc.
Index- P/E- EPS (ttm)- Insider Own5.44% Shs Outstand20.98M Perf Week12.79%
Market Cap602.67M Forward P/E- EPS next Y-2.29 Insider Trans0.00% Shs Float19.84M Perf Month21.61%
Income- PEG- EPS next Q-0.41 Inst Own85.50% Short Float1.47% Perf Quarter93.58%
Sales- P/S- EPS this Y-34.90% Inst Trans4.86% Short Ratio2.42 Perf Half Y-
Book/sh4.32 P/B7.13 EPS next Y42.70% ROA- Target Price35.00 Perf Year-
Cash/sh4.85 P/C6.34 EPS next 5Y- ROE- 52W Range12.50 - 37.88 Perf YTD6.06%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-18.74% Beta-
Dividend %- Quick Ratio12.30 Sales past 5Y- Gross Margin- 52W Low146.24% ATR2.83
Employees24 Current Ratio12.30 Sales Q/Q- Oper. Margin- RSI (14)59.40 Volatility10.15% 10.71%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.31 Prev Close31.88
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume120.73K Price30.78
Recom1.60 SMA2010.05% SMA5019.26% SMA20041.47% Volume36,924 Change-3.45%
Dec-22-20Initiated Cantor Fitzgerald Overweight $42
Oct-20-20Initiated Wedbush Outperform $41
Oct-20-20Initiated SVB Leerink Outperform $35
Oct-20-20Initiated Piper Sandler Overweight $27
Oct-20-20Initiated Oppenheimer Outperform $41
Oct-20-20Initiated Needham Buy $30
Jan-07-21 07:30AM  
Dec-25-20 02:06AM  
Dec-10-20 04:50PM  
Nov-16-20 04:05PM  
Nov-12-20 04:05PM  
Oct-27-20 07:48PM  
Oct-14-20 04:42AM  
Oct-01-20 11:57AM  
Sep-25-20 02:31PM  
Sep-24-20 08:12PM  
Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.